Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
Shinnakasu R, Sakakibara S, Yamamoto H, Wang PH, Moriyama S, Sax N, Ono C, Yamanaka A, Adachi Y, Onodera T, Sato T, Shinkai M, Suzuki R, Matsuura Y, Hashii N, Takahashi Y, Inoue T, Yamashita K, Kurosaki T.
Shinnakasu R, et al. Among authors: inoue t.
J Exp Med. 2021 Dec 6;218(12):e20211003. doi: 10.1084/jem.20211003. Epub 2021 Oct 8.
J Exp Med. 2021.
PMID: 34623376
Free PMC article.